Ignyta (RXDX) Announces Encouraging Interim RXDX-105 Phase 1 Data
Tweet Send to a Friend
Ignyta, Inc. (Nasdaq: RXDX) announced that interim results from the Phase 1 clinical trial of RXDX-105, the company’s orally available ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
